- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Drug Pipelines
- November 2020
- 68 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- January 2024
- 142 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- August 2021
- 138 Pages
Global
From €3200EUR$3,523USD£2,837GBP
- Report
- October 2022
- 42 Pages
Global
From €1946EUR$2,000USD£1,667GBP
The Oral Herpes Drug market is a subset of the Infectious Diseases Drugs market. It is composed of drugs used to treat the herpes simplex virus (HSV) infection, which is a common and highly contagious virus. Oral Herpes Drugs are typically antiviral medications that work by inhibiting the replication of the virus. These drugs are used to reduce the severity and duration of symptoms, as well as to reduce the risk of transmission. Common side effects of Oral Herpes Drugs include nausea, headache, and dizziness.
The Oral Herpes Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Sanofi. Other companies in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson. Show Less Read more
